Physician profile
Bashar Nasour Mohamad
NPI 1225311665
$2,686.28
in general payments reported to CMS, 2019-2025
22 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $148 · 2021: $197 · 2022: $126 · 2023: $297 · 2024: $252 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Food and Beverage | $781.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,263.78 | 2024-2025 | Epclusa, Veklury |
| Abbvie INC. | $629.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.77 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.92 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $88.81 | 2022-2023 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $76.30 | 2024 | Imjudo |
| Janssen Biotech, INC. | $67.90 | 2020-2025 | Tremfya |
| Olympus America INC. | $52.93 | 2020 | |
| Intercept Pharmaceuticals, INC. | $43.16 | 2019-2023 | Ocaliva |
| Ucb, INC. | $21.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.10 | 2023 | Dupixent |
| Alexion Pharmaceuticals, INC. | $21.04 | 2019 | |
| Smith+Nephew, INC. | $19.75 | 2025 | Pico 7 |
| Novo Nordisk INC | $18.43 | 2025 | Wegovy |
| Eisai INC. | $17.18 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15.51 | 2025 | |
| Dynavax Technologies Corporation | $15.32 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.39 | 2019 | |
| Qol Medical, LLC | $14.36 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.32 | 2022 | |
| Celgene Corporation | $12.49 | 2022 | |
| Shionogi INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Mohamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.